Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06120530 · ClinicalTrials.gov registry record · Phase 4
Intraperitoneal Bupivacaine for Pelvic Organ Prolapse
A Phase 4 study, sponsored by Indiana University.
- Completed
- Registry status
- Phase 4
- Development phase
- 91
- Enrollment target
NCT06120530 is a Phase 4 study that has completed, run by Indiana University. The registered enrollment target is 91 participants.
The verdict
NCT06120530, a Phase 4 study, has completed, sponsored by Indiana University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 91 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effects of 30 mL intraperitoneal Bupivacaine without epinephrine 0.25% on postoperative pain control in patients undergoing pelvic organ prolapse repair. The investigators hypothesize that use of intraperitoneal Bupivacaine will decrease postoperative pain scores and opiate consumption in the postoperative period, following pelvic organ prolapse repair.
Interventions
- DRUG Bupivacaine
- OTHER Saline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 91 participants |
| Start Date | 2023-08-16 |
| Est. Completion | 2024-03-15 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06120530
The ClinicalTrials.gov registry entry for NCT06120530 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 91 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Bupivacaine is the first listed.
NCT06120530 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06120530 about?
NCT06120530 is a clinical study titled "Intraperitoneal Bupivacaine for Pelvic Organ Prolapse". The purpose of this study is to evaluate the effects of 30 mL intraperitoneal Bupivacaine without epinephrine 0.25% on postoperative pain control in patients undergoing pelvic organ prolapse repair. The investigators hypothesize that use of intraperitoneal Bupivacaine will decrease postoperative pai...
What is the current status of trial NCT06120530?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 91 participants. The study started on 2023-08-16. Estimated completion is 2024-03-15.
What interventions are being tested in trial NCT06120530?
The interventions under investigation include: Bupivacaine (DRUG), Saline (OTHER).
Who is sponsoring clinical trial NCT06120530?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.